- Home
- PRT vs IXHL Comparison
PRT vs IXHL Comparison
Compare PRT & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRT
- IXHL
- Stock Information
- Founded
- PRT 2017
- IXHL 2001
- Country
- PRT United States
- IXHL Australia
- Employees
- PRT N/A
- IXHL N/A
- Industry
- PRT Oil & Gas Production
- IXHL
- Sector
- PRT Energy
- IXHL
- Exchange
- PRT Nasdaq
- IXHL Nasdaq
- Market Cap
- PRT 47.7M
- IXHL 54.5M
- IPO Year
- PRT N/A
- IXHL N/A
- Fundamental
- Price
- PRT $3.79
- IXHL $0.53
- Analyst Decision
- PRT
- IXHL
- Analyst Count
- PRT 0
- IXHL 0
- Target Price
- PRT N/A
- IXHL N/A
- AVG Volume (30 Days)
- PRT 35.0K
- IXHL 114.7M
- Earning Date
- PRT 11-12-2025
- IXHL 11-13-2025
- Dividend Yield
- PRT 11.43%
- IXHL N/A
- EPS Growth
- PRT 1.16
- IXHL N/A
- EPS
- PRT 0.44
- IXHL N/A
- Revenue
- PRT $6,314,770.00
- IXHL $98,000.00
- Revenue This Year
- PRT N/A
- IXHL $2,538.49
- Revenue Next Year
- PRT N/A
- IXHL $249.95
- P/E Ratio
- PRT $8.65
- IXHL N/A
- Revenue Growth
- PRT 1.82
- IXHL N/A
- 52 Week Low
- PRT $3.26
- IXHL $0.08
- 52 Week High
- PRT $4.63
- IXHL $3.12
- Technical
- Relative Strength Index (RSI)
- PRT 33.58
- IXHL 47.23
- Support Level
- PRT $3.84
- IXHL $0.50
- Resistance Level
- PRT $3.89
- IXHL $0.59
- Average True Range (ATR)
- PRT 0.08
- IXHL 0.05
- MACD
- PRT -0.02
- IXHL -0.01
- Stochastic Oscillator
- PRT 5.29
- IXHL 6.31
About PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.